Lung Cancer | University of Iowa Clinical Research and Trials

Attention Site Visitor

You are currently visiting the UI Health Care Clinical Trials website on a version of the web browser: Internet Explorer. Internet Explorer is no longer being supported by Microsoft, and there are features and functionality on this website that does not operate properly when using Internet Explorer. If you have an alternative browser, such as: Microsoft Edge, Google Chrome, Mozilla Firefox, or Apple Safari, we suggest you switch to that browser for the optimal viewing experience.

Thank you

ALLIANCE A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Cancer Internal Medicine Lung Cancer Adult Subjects Female Subjects Male Subjects

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Cancer Internal Medicine Lung Cancer Melanoma Skin Cancer Adult Subjects Female Subjects Male Subjects

The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, non-melanoma skin cancer (NMSC), and non-small cell lung cancer (NSCLC).